Pain Therapeutics (PTIE) 5.38 $PTIE
Pain Therapeutics Shares Up 71.4% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 15, 9:40AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 71.43% as of today's recent price of $5.22.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Pain Therapeutics Shares Up 85.6% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 08, 9:09AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65.
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Tue Apr 08, 8:00AM CDT
Research and Markets ( http://www.researchandmarkets.com/research/33...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/33sf9j/pain_therapeutics ] to their offering.
GW Pharmaceuticals talk Cannabinoids
PRWeb - Mon Apr 07, 12:18PM CDT
The industry established Pain Therapeutics conference for combining new pain therapeutic developments with essential networking and collaboration opportunities, will be taking place on 19th and 20th May at the Holiday Inn Kensington Forum, London.
Pain Therapeutics Has Returned 79.0% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Mon Mar 31, 4:43PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 78.98% as of today's recent price of $5.45.
Janssen Pharmaceutical to Provide Exclusive Update on Fulranumab Clinical Development
PRWeb - Thu Mar 20, 9:42AM CDT
SMi Group have worked together with an esteemed panel of speakers including KOLs from Merck, Janssen Pharmaceuticals, Imperial College London, Mundipharma, Nektar Pharmaceuticals, Morpheus and Eli Lilly, to put together the conference agenda for the 14th annual Pain Therapeutics event taking place on 19th and 20th May in Central London.
Pain Therapeutics Up 83.6% Since SmarTrend Uptrend Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 17, 9:36AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 83.58% as of today's recent price of $5.59.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 14, 7:24PM CDT
It's almost time to start buying domestic growth stocks, Cramer says.
77.2% Return Seen to Date on SmarTrend Pain Therapeutics Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 10, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 77.16% as of today's recent price of $5.39.
Pain Therapeutics Invited to Present at 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:24AM CST
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at ROTH Capital Partners' 26th Annual ROTH Conference on Monday, March 10 at 12:30 p.m. Pacific Time at the Ritz-Carlton, Laguna Niguel in Dana Point, California.
Pain Therapeutics (PTIE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:40AM CST
Pain Therapeutics (PTIE) Enters Overbought Territory
Shares of PTIE Up 85.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 4:42PM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65.
Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston
GlobeNewswire - Tue Feb 25, 9:25AM CST
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at Cowen and Company's 34 Annual Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time at the Copley Place Hotel.
Pain Therapeutics Earnings Hindsight: Up 35.2% in Last 20 Days (PTIE)
Comtex SmarTrend(R) - Mon Feb 24, 7:18AM CST
When Pain Therapeutics (NASDAQ TIE) reported earnings two weeks ago on February 4th, 2014, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.0 million. The company actually reported EPS of $0.72 on sales of $35.2 million, beating EPS estimates by $0.73 and beating revenue estimates by $33.2 million. Since the company's report, shares of Pain Therapeutics have risen from $3.92 to $5.30, representing a gain of 35.2% in the past 20 days.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
Pain Therapeutics Shares Up 71.4% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 15, 9:40AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 71.43% as of today's recent price of $5.22. Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Pain Therapeutics Shares Up 85.6% Since SmarTrend's Buy Recommendation (PTIE)
Comtex SmarTrend(R) - Tue Apr 08, 9:09AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 8 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65. Pain Therapeutics - Drugs, Markets and Companies
PR Newswire Europe - Tue Apr 08, 8:00AM CDT
Research and Markets ( http://www.researchandmarkets.com/research/33...rapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/33sf9j/pain_therapeutics ] to their offering.
GW Pharmaceuticals talk Cannabinoids
PRWeb - Mon Apr 07, 12:18PM CDT
The industry established Pain Therapeutics conference for combining new pain therapeutic developments with essential networking and collaboration opportunities, will be taking place on 19th and 20th May at the Holiday Inn Kensington Forum, London.
Pain Therapeutics Has Returned 79.0% Since SmarTrend Recommendation (PTIE)
Comtex SmarTrend(R) - Mon Mar 31, 4:43PM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 78.98% as of today's recent price of $5.45. Janssen Pharmaceutical to Provide Exclusive Update on Fulranumab Clinical Development
PRWeb - Thu Mar 20, 9:42AM CDT
SMi Group have worked together with an esteemed panel of speakers including KOLs from Merck, Janssen Pharmaceuticals, Imperial College London, Mundipharma, Nektar Pharmaceuticals, Morpheus and Eli Lilly, to put together the conference agenda for the 14th annual Pain Therapeutics event taking place on 19th and 20th May in Central London.
Pain Therapeutics Up 83.6% Since SmarTrend Uptrend Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 17, 9:36AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 83.58% as of today's recent price of $5.59. Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 14, 7:24PM CDT
It's almost time to start buying domestic growth stocks, Cramer says.
77.2% Return Seen to Date on SmarTrend Pain Therapeutics Call (PTIE)
Comtex SmarTrend(R) - Mon Mar 10, 9:08AM CDT
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 7 months, Pain Therapeutics has returned 77.16% as of today's recent price of $5.39. Pain Therapeutics Invited to Present at 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:24AM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at ROTH Capital Partners' 26th Annual ROTH Conference on Monday, March 10 at 12:30 p.m. Pacific Time at the Ritz-Carlton, Laguna Niguel in Dana Point, California. Pain Therapeutics (PTIE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:40AM CST
Pain Therapeutics (PTIE) Enters Overbought Territory
Shares of PTIE Up 85.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 4:42PM CST
SmarTrend identified an Uptrend for Pain Therapeutics (NASDAQ
TIE) on August 19th, 2013 at $3.05. In approximately 6 months, Pain Therapeutics has returned 85.55% as of today's recent price of $5.65. Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston
GlobeNewswire - Tue Feb 25, 9:25AM CST
Pain Therapeutics, Inc. (Nasdaq
TIE) today announced that Remi Barbier, Chairman, President & CEO, will present at Cowen and Company's 34 Annual Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time at the Copley Place Hotel. Pain Therapeutics Earnings Hindsight: Up 35.2% in Last 20 Days (PTIE)
Comtex SmarTrend(R) - Mon Feb 24, 7:18AM CST
When Pain Therapeutics (NASDAQ
TIE) reported earnings two weeks ago on February 4th, 2014, analysts, on average, expected the company to report a loss of $0.01 on sales of $2.0 million. The company actually reported EPS of $0.72 on sales of $35.2 million, beating EPS estimates by $0.73 and beating revenue estimates by $33.2 million. Since the company's report, shares of Pain Therapeutics have risen from $3.92 to $5.30, representing a gain of 35.2% in the past 20 days. Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
